| Literature DB >> 34966839 |
Madeleine Orban1,2, Dominic Dischl1,2, Christoph Müller3, Sarah Ulrich4, Tobias Petzold1,2, Konstantinos Rizas1,2, Martin W Orban1, Daniel Braun1, Jörg Hausleiter1,2, Christian Hagl3,2, Julinda Mehilli1,2, Steffen Massberg1,2.
Abstract
BACKGROUND: The development and progression of cardiac allograft vasculopathy documented by coronary angiography (CAVangio) after heart transplantation (HTx) has prognostic relevance. Yet there are limited data regarding the role of concomitant intracoronary imaging in the presence CAVangio. In particular, atherosclerotic plaques might represent a potential target for prevention, but their impact on stenosis is understudied.Entities:
Year: 2021 PMID: 34966839 PMCID: PMC8710340 DOI: 10.1097/TXD.0000000000001266
Source DB: PubMed Journal: Transplant Direct ISSN: 2373-8731
FIGURE 1.Representative optical coherence tomography (OCT) findings. A, Example of eccentric intimal hyperplasia. The blue line represents the intima measurement; the red line represents the media measurement in one quadrant. B, Circular calcified plaque. C, Lipid plaque. D, Fibrotic plaque. Border between lateral plaque borders and normal vessel wall are delineated and thereby the arc of the plaque is measured.
Population characteristics
| Characteristics (n = 65) | |
|---|---|
| Male sex, n (%) | 54 (83.1) |
| Age at OCT, y | 56.8 ± 12.5 |
| Posttransplant interval, y | 9.9 ± 7.6 |
| CAVangio, | 43 (66.2) |
| Severity of angiographic stenosis in the analyzed vessel | |
| Nondetectable stenosis, n (%) | 22 (33.8) |
| Nonsevere stenosis, n (%) | 31 (47.7) |
| Severe stenosis, n (%) | 12 (18.5) |
| ISHLT CAV grade | |
| ISHLT CAV grade 0, n (%) | 20 (30.8) |
| ISHLT CAV grade 1, n (%) | 30 (46.2) |
| ISHLT CAV grade 2 and 3, | 15 (23.1) |
| Reason for index HTx | |
| Ischemic cardiomyopathy, n (%) | 17 (26.2) |
| Dilated cardiomyopathy, n (%) | 30 (46.2) |
| Others, | 18 (27.7) |
| Medication at OCT | |
| Prednisolone, n (%) | 4 (6.2) |
| Tacrolimus, n (%) | 51 (78.5) |
| Cyclosporine, n (%) | 5 (7.7) |
| Everolimus, n (%) | 8 (12.3) |
| Sirolimus, n (%) | 16 (24.6) |
| Mycophenolate, n (%) | 50 (76.9) |
| Statin, n (%) | 54 (83.1) |
Data are shown as mean ± SD or n (%).
CAVangio and severity of angiographic stenosis were defined according to the standard classification of the ISHLT in primary vessels.
Includes patients having undergone PCI in another vessel due to high-grade CAV (ISHLT CAV grades 2 and 3).
Others include myocarditis, peripartal cardiomyopathy, retransplantation, and restrictive cardiomyopathy.
CAVangio, angiographic manifest cardiac allograft vasculopathy; HTx, heart transplantation; ISHLT, International Society for Heart and Lung Transplantation; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.
FIGURE 2.Optical coherence tomography (OCT) findings in patients with and without angiographic manifest cardiac allograft vasculopathy (CAVangio). Patients without CAVangio, n = 22. Patients with CAVangio, n = 43. A, Prevalence of absolute and relative CAVIH. Maximal intimal thickness (IT) >0.3 mm denotes absolute CAVIH. Maximal intima-media ratio (I/M) >3 denotes relative CAVIH with a cutoff of I/M >3. B, Prevalence of fibrotic, lipid, and calcified plaques. CAVangio was defined according to the classification of the International Society for Heart and Lung Transplantation (ISHLT) as ISHLT CAV grade >0 in the analyzed vessel. P values are shown for χ2 test.
Association of OCT findings with CAVangio at vessel level
| Factor | Odds ratio (95% CI) |
|---|---|
| Intimal hyperplasia | |
| Absolute intimal hyperplasia | 4.48 (1.48-13.58) |
| Relative intimal hyperplasia with I/M >2 | 1.46 (0.30-7.20) |
| Relative intimal hyperplasia with I/M >3 | 4.27 (1.39-13.06) |
| Plaques morphologies | |
| Fibrotic plaques | 8.10 (2.54-25.81) |
| Calcified plaques | 13.73 (1.69-111.81) |
| Lipid plaques | 32.57 (7.55-140.57) |
CAVangio, angiographic manifest cardiac allograft vasculopathy; CI, confidence interval; I/M, intima-media ratio; OCT, optical coherence tomography.
OCT findings according to angiographic stenosis severity at vessel level
| Nondetectable stenosis, n = 22 | Nonsevere stenosis, n = 31 | Severe stenosis, n = 12 |
| |
|---|---|---|---|---|
| Intimal hyperplasia | ||||
| Patients with maximal IT >0.3 mm, n (%) | 9 (40.9) | 23 (74.2) | 8 (66.7) | 0.02 |
| Patients with maximal I/M >3 | 8 (36.4) | 24 (77.4) | 8 (66.7) | 0.03 |
| Maximal IT, mm | 0.3 ± 0.1 | 0.5 ± 0.4 | 0.5 ± 0.3 | 0.006 |
| Mean IT, mm | 0.1 ± 0.1 | 0.2 ± 0.2 | 0.2 ± 0.1 | 0.002 |
| Maximal I/M | 3.1 ± 1.1 | 6.2 ± 3.9 | 5.4 ± 4.1 | 0.004 |
| Mean I/M | 1.6 ± 0.5 | 2.5 ± 1.2 | 2.4 ± 1.3 | 0.004 |
| Fibrotic plaque | ||||
| Patients with fibrotic plaque, n (%) | 7 (31.8) | 24 (77.4) | 10 (83.3) | 0.001 |
| Relative plaque length, % | 55.0 ± 44.4 | 72.4 ± 26.5 | 77.9 ± 24.3 | 0.045 |
| Maximal fibrotic arc, deg | 306.6 ± 57.1 | 343.6 ± 36.1 | 360.0 ± 0.0 | 0.05 |
| Mean fibrotic arc, deg | 215.1 ± 14.3 | 250.0 ± 42.7 | 289.8 ± 46.0 | 0.001 |
| Lipid plaque | ||||
| Patients with lipid plaque, n (%) | 3 (13.6) | 25 (80.6) | 11 (91.7) | <0.001 |
| Relative plaque length, % | 18.6 ± 9.8 | 40.6 ± 34.9 | 56.1 ± 30.5 | 0.2 |
| Maximal lipid arc, deg | 167.9 ± 53.3 | 205.8 ± 89.8 | 241.0 ± 68.9 | 0.3 |
| Mean lipid arc, deg | 127.1 ± 28.9 | 123.8 ± 43.7 | 139.3 ± 40.7 | 0.9 |
| Calcified plaque | ||||
| Patients with calcified plaque, n (%) | 1 (4.5) | 11 (35.5) | 6 (50.0) | 0.007 |
| Relative plaque length, % | NA | 30.5 ± 25.8 | 28.0 ± 29.5 | 0.6 |
| Maximal calcified arc, deg | NA | 184.5 ± 87.4 | 186.8 ± 106.5 | 0.06 |
| Mean calcified arc, deg | NA | 104.6 ± 87.4 | 144.1 ± 98.8 | 0.38 |
indicates significant differences between groups with P < 0.05.
Data are shown as mean (±SD) or n (%). Relative plaque length was defined as percentage of the plaque length in relation to the overall length of the vessel analyzed in OCT.
deg, arc degree; I/M, intima-media ratio; IT, intimal thickness; NA, not available; OCT, optical coherence tomography.
Correlation of OCT findings with severity of angiographic stenosis at vessel level
|
|
| |
|---|---|---|
| Intimal hyperplasia | ||
| Maximal IT, mm | 0.39 | 0.002 |
| Mean IT, mm | 0.43 | <0.001 |
| Maximal I/M | 0.32 | 0.01 |
| Mean I/M | 0.39 | 0.001 |
| Fibrotic plaque | ||
| Relative plaque length, % | 0.32 | 0.04 |
| Maximal fibrotic arc, deg | 0.33 | 0.03 |
| Mean fibrotic arc, deg | 0.52 | <0.001 |
| Lipid plaque | ||
| Relative plaque length, % | 0.40 | 0.01 |
| Maximal lipid arc, deg | 0.32 | 0.05 |
| Mean lipid arc, deg | 0.22 | 0.2 |
| Calcified plaque | ||
| Relative plaque length, % | 0.02 | 0.9 |
| Maximal calcified arc, deg | −0.2 | 0.5 |
| Mean calcified arc, deg | −0.09 | 0.7 |
indicates significant correlation with with P < 0.05.
deg, arc degree; I/M, intima-media ratio; IT, intimal thickness; OCT, optical coherence tomography.
FIGURE 3.Receiver operating characteristic curves of relevant optical coherence tomography (OCT) parameters contributing to the presence of angiographic manifest cardiac allograft vasculopathy (CAVangio). AUC, area under the curve; CI, confidence interval; I/M, intima-media ratio; IT, intimal thickness.
Association of OCT findings with overall CAVangio at patient level
| Factor | Overall CAVangio | |
|---|---|---|
| ISHLT CAV grade 1 | ISHLT CAV grades 2 and 3 | |
| Intimal hyperplasia | ||
| Absolute intimal hyperplasia | 2.07 (0.72-5.98) | 2.53 (0.63-10.23) |
| Relative intimal hyperplasia with I/M >2 | 1.16 (0.24-5.65) | 1.81 (0.20-16.47) |
| Relative intimal hyperplasia with I/M >3 | 3.03 (0.98-9.32) | 2.13 (0.52-8.66) |
| Plaques morphologies | ||
| Fibrotic plaques | 3.10 (1.06-9.09) | 1.83 (0.51-6.57) |
| Lipid plaques | 3.90 (1.33-11.45) | 6.00 (1.23-29.39) |
| Calcified plaques | 2.32 (0.76-7.04) | 2.11 (0.62-7.15) |
includes patients having undergone PCI in another vessel due to high-grade CAV (ISHLT CAV grades 2 and 3).
indicates significant association with P <0.05.
Data are shown as odds ratio (95% CI).
CAVangio, angiographic manifest cardiac allograft vasculopathy; CI, confidence interval; I/M, intima-media ratio; ISHLT, International Society for Heart and Lung Transplantation; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.